109 related articles for article (PubMed ID: 31319387)
1. PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change.
Tsai KK; Khurana N; McCalmont T; Daud A; Bastian B; Yeh I
J Natl Compr Canc Netw; 2019 Jul; 17(7):778-783. PubMed ID: 31319387
[TBL] [Abstract][Full Text] [Related]
2. Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report.
Wu MJ; Chen YC; Cui XL; Yang Q; Xue QL
Medicine (Baltimore); 2023 May; 102(19):e33788. PubMed ID: 37171300
[TBL] [Abstract][Full Text] [Related]
3. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
4. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.
Cohen PR; Kato S; Goodman AM; Ikeda S; Kurzrock R
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788102
[TBL] [Abstract][Full Text] [Related]
5. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
Falchook GS; Leidner R; Stankevich E; Piening B; Bifulco C; Lowy I; Fury MG
J Immunother Cancer; 2016; 4():70. PubMed ID: 27879972
[TBL] [Abstract][Full Text] [Related]
6. Basal cell carcinoma and its development: insights from radiation-induced tumors in Ptch1-deficient mice.
Mancuso M; Pazzaglia S; Tanori M; Hahn H; Merola P; Rebessi S; Atkinson MJ; Di Majo V; Covelli V; Saran A
Cancer Res; 2004 Feb; 64(3):934-41. PubMed ID: 14871823
[TBL] [Abstract][Full Text] [Related]
7. Mutations in SUFU and PTCH1 genes may cause different cutaneous cancer predisposition syndromes: similar, but not the same.
Huq AJ; Walsh M; Rajagopalan B; Finlay M; Trainer AH; Bonnet F; Sevenet N; Winship IM
Fam Cancer; 2018 Oct; 17(4):601-606. PubMed ID: 29356994
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
[TBL] [Abstract][Full Text] [Related]
9. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.
Lipson EJ; Lilo MT; Ogurtsova A; Esandrio J; Xu H; Brothers P; Schollenberger M; Sharfman WH; Taube JM
J Immunother Cancer; 2017; 5():23. PubMed ID: 28344809
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.
Fischer S; Hasan Ali O; Jochum W; Kluckert T; Flatz L; Siano M
Oncol Res Treat; 2018; 41(6):391-394. PubMed ID: 29734143
[TBL] [Abstract][Full Text] [Related]
11. Nevoid Basal Cell Carcinoma Syndrome:
Martinez MF; Romano MV; Martinez AP; González A; Muchnik C; Stengel FM; Mazzuoccolo LD; Azurmendi PJ
Cells; 2019 Feb; 8(2):. PubMed ID: 30754660
[TBL] [Abstract][Full Text] [Related]
12. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
14. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
[TBL] [Abstract][Full Text] [Related]
15. Unique features of PTCH1 mutation spectrum in Chinese sporadic basal cell carcinoma.
Huang YS; Bu DF; Li XY; Ma ZH; Yang Y; Lin ZM; Lu FM; Tu P; Li H
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):235-41. PubMed ID: 22313357
[TBL] [Abstract][Full Text] [Related]
16. [Not Available].
Basset-Seguin N
Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Patched-1 Protein Expression Level in Low Risk and High Risk Basal Cell Carcinoma Subtypes.
Almomani R; Khanfar M; Bodoor K; Al-Qarqaz F; Alqudah M; Hammouri H; Abu-Salah A; Haddad Y; Al Gargaz W; Mohaidat Z
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2851-2857. PubMed ID: 31554387
[TBL] [Abstract][Full Text] [Related]
18. Novel PTCH1 and concurrent TP53 mutations in four patients with numerous non-syndromic basal cell carcinomas: The paradigm of oncogenic synergy.
Dasgeb B; Pajouhanfar S; Jazayeri A; Schoenberg E; Kumar G; Fortina P; Berger AC; Uitto J
Exp Dermatol; 2022 May; 31(5):736-742. PubMed ID: 34862824
[TBL] [Abstract][Full Text] [Related]
19. Patched-2 functions to limit Patched-1 deficient skin cancer growth.
Veenstra VL; Dingjan I; Waasdorp C; Damhofer H; van der Wal AC; van Laarhoven HW; Medema JP; Bijlsma MF
Cell Oncol (Dordr); 2018 Aug; 41(4):427-437. PubMed ID: 29869097
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Basal Cell Carcinoma.
Laga AC; Schaefer IM; Sholl LM; French CA; Hanna J
Am J Clin Pathol; 2019 Nov; 152(6):706-717. PubMed ID: 31355851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
